ATP2A2 Antibody

What is ATP2A2 and why is it important in cellular research?

ATP2A2, also known as SERCA2 (Sarcoplasmic/Endoplasmic Reticulum Calcium ATPase 2), is an ATPase encoded by the ATP2A2 gene in humans. It plays a crucial role in calcium homeostasis by catalyzing the hydrolysis of ATP coupled with the translocation of calcium from the cytosol into the endoplasmic reticulum lumen. This mechanism is fundamental for various cellular processes including muscle contraction, cell signaling, and endoplasmic reticulum function. Mutations in the ATP2A2 gene are associated with Darier-White disease (keratosis follicularis), an autosomal dominant skin disorder characterized by abnormal keratinization and loss of adhesion between epidermal cells . Due to its critical role in calcium regulation, ATP2A2 is also implicated in heart failure, muscular disorders, and various neurodegenerative conditions, making it an important target for biomedical research .

What applications are ATP2A2 antibodies validated for?

ATP2A2 antibodies are validated for multiple experimental applications:

For Western blot applications, ATP2A2 typically appears as a band at approximately 114 kDa. Specific protocols have been validated, such as using 5-20% SDS-PAGE gels run at 70V (stacking gel) and 90V (resolving gel), with protein transfer to nitrocellulose membranes at 150 mA for 50-90 minutes .

How should ATP2A2 antibodies be stored to maintain optimal activity?

Proper storage of ATP2A2 antibodies is critical for maintaining their activity and specificity. Based on manufacturer recommendations:

• Store lyophilized antibodies at -20°C for up to one year from the date of receipt .

• After reconstitution, store at 4°C for one month or aliquot and store at -20°C for up to six months .

• Avoid repeated freeze-thaw cycles as they can significantly decrease antibody activity .

• Some ATP2A2 antibodies, such as the BiCell Scientific product, are stored in PBS (pH 7.2) with 0.1% sodium azide and should be maintained at -20°C .

Researchers should always consult specific product documentation, as storage conditions may vary slightly between manufacturers and product formulations.

What species reactivity can be expected with common ATP2A2 antibodies?

ATP2A2 antibodies exhibit varying species reactivity profiles:

Most commercial ATP2A2 antibodies are raised against highly conserved regions of the protein, explaining the cross-reactivity across multiple species. For instance, the immunogen for PA1720 is a synthetic peptide corresponding to a sequence in the middle region of human SERCA2 ATPase (665-679aa QRDACLNARCFARVE), which is identical to the related rat and mouse sequences . Similarly, the BiCell Scientific antibody's immunogen (from the N-terminal cytoplasmic region) shows identical sequence homology between human, mouse, and rat .

How can researchers distinguish between ATP2A2 isoforms using antibodies?

ATP2A2 has multiple isoforms resulting from alternative splicing. When selecting antibodies for isoform-specific detection, researchers should:

• Examine the immunogen sequence carefully - determine if the antibody was raised against a region common to all isoforms or specific to particular variants.

• Perform validation experiments with positive controls expressing known isoforms.

• Consider using complementary techniques like RT-PCR to confirm isoform expression.

For example, when a researcher asked if the PA1720 antibody is reactive to specific isotypes of ATP2A2, the manufacturer noted that the immunogen corresponds to a sequence in the middle region of human SERCA2 ATPase (665-679aa) . Researchers needing to detect specific isoforms should verify whether this region is present in their isoform of interest by sequence alignment analysis.

What are the critical controls needed when using ATP2A2 antibodies for experimental validation?

Proper experimental controls are essential for validating ATP2A2 antibody results:

• Positive controls: Include tissues or cells known to express ATP2A2, such as:

  • Cardiac muscle (high SERCA2 expression)

  • Skeletal muscle tissue (as used in the PA1720 validation)

  • PANC and SMMC cell lysates (validated with PA1720)

• Negative controls:

  • Primary antibody omission

  • Tissues from knockout models (if available)

  • Preabsorption with immunizing peptide

• Loading controls:

  • For Western blots, include housekeeping proteins (β-actin, GAPDH)

  • For IHC/IF, include nuclear counterstains and examine tissues with variable expression

• Antibody specificity controls:

  • Test specificity by RNA interference or CRISPR knockout validation

  • Confirm molecular weight with protein standards

These controls help determine antibody specificity and minimize false positive or negative results.

How do experimental conditions impact ATP2A2 antibody performance in Western blotting?

Various experimental factors significantly affect ATP2A2 antibody performance in Western blotting:

• Sample preparation:

  • Optimal lysis buffers should preserve protein structure while effectively extracting membrane proteins

  • Use of protease inhibitors is essential as ATP2A2 may be susceptible to degradation

  • Heat denaturation temperatures may affect epitope exposure

• Electrophoretic conditions:

  • For optimal resolution of ATP2A2 (114 kDa), use 5-20% gradient SDS-PAGE gels

  • Run conditions: 70V for stacking gel, 90V for resolving gel for 2-3 hours

  • Load approximately 30 μg of protein per lane under reducing conditions

• Transfer parameters:

  • Transfer to nitrocellulose membrane at 150 mA for 50-90 minutes

  • Extended transfer times may be required for complete transfer of this large protein

• Blocking and antibody incubation:

  • 5% milk in TBST for 1.5 hours at room temperature is effective for blocking

  • Primary antibody dilution: 1:1000 overnight at 4°C

  • Secondary antibody (goat anti-rabbit IgG-HRP): 1:1000 for 1 hour at room temperature

• Detection methods:

  • Enhanced Chemiluminescent detection (ECL) systems have been validated for ATP2A2 detection

Optimization of these parameters may be necessary for different experimental systems.

What methodological approaches can resolve contradictory ATP2A2 antibody data?

When researchers encounter contradictory results with ATP2A2 antibodies, several methodological approaches can help resolve discrepancies:

• Multiple antibody validation:

  • Test different antibodies targeting distinct epitopes of ATP2A2

  • Compare polyclonal (e.g., PA1720, CAB0098) and monoclonal antibodies

  • Evaluate batch-to-batch variation by requesting validation data from manufacturers

• Complementary techniques:

  • Confirm protein expression with mass spectrometry

  • Validate gene expression with RT-qPCR

  • Use proximity ligation assays for protein-protein interaction verification

• Cell/tissue-specific considerations:

  • ATP2A2 expression and localization may vary by cell type

  • Subcellular fractionation can help verify endoplasmic reticulum localization

  • Consider tissue-specific post-translational modifications

• Quantification methods:

  • Employ multiple normalization strategies

  • Use digital image analysis with appropriate thresholding

  • Apply statistical analysis to determine significance of observed differences

Implementing these approaches provides more robust data interpretation and helps reconcile contradictory findings.

How can researchers optimize immunohistochemistry protocols for ATP2A2 detection?

Successful immunohistochemical detection of ATP2A2 requires careful protocol optimization:

• Fixation and antigen retrieval:

  • Formalin-fixed, paraffin-embedded tissues require appropriate antigen retrieval

  • Heat-induced epitope retrieval using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

  • Optimization of retrieval time (10-20 minutes) based on tissue type

• Antibody dilution and incubation:

  • Start with recommended dilutions (1:50 - 1:100 for IHC-P with CAB0098)

  • Optimize primary antibody incubation time and temperature (typically overnight at 4°C)

  • Consider signal amplification systems for low-expression tissues

• Detection systems:

  • For brightfield microscopy: HRP/DAB systems work well with ATP2A2 antibodies

  • For fluorescence: select secondary antibodies with appropriate fluorophores

  • Use tyramide signal amplification for enhanced sensitivity if needed

• Tissue-specific considerations:

  • Human mammary cancer tissue has been successfully used with PA1720

  • Mouse heart tissue serves as a positive control for CAB0098

  • Include tissues with known differential expression of ATP2A2

• Background reduction strategies:

  • Careful blocking with appropriate sera or BSA

  • Include avidin/biotin blocking if using biotin-based detection systems

  • Consider autofluorescence quenching for fluorescence applications

Researchers should document all optimization steps for reproducibility and method reporting.

What are the most common issues when working with ATP2A2 antibodies and how can they be resolved?

Researchers frequently encounter specific challenges when working with ATP2A2 antibodies:

For example, when a customer inquired about using PA1720 (validated for human, mouse, and rat) with feline tissues, the manufacturer noted that while not specifically tested, there was "a good chance of cross-reactivity" due to sequence conservation, highlighting the importance of empirical validation for non-listed species .

How should researchers approach ATP2A2 quantification in comparative studies?

Accurate quantification of ATP2A2 in comparative studies requires careful experimental design and analysis:

• Experimental design considerations:

  • Include appropriate controls for each experimental condition

  • Process all samples simultaneously to minimize technical variation

  • Balance biological replicates across experimental groups

• Western blot quantification:

  • Use validated housekeeping proteins as loading controls

  • Apply linear range detection methods (avoid saturated signals)

  • Normalize ATP2A2 signal to loading controls

  • Employ digital image analysis software with consistent ROI selection

• Immunohistochemistry quantification:

  • Use consistent image acquisition parameters

  • Apply automated analysis methods to reduce subjective bias

  • Employ multiple fields per sample (minimum 5-10 fields)

  • Report intensity measures alongside percentage of positive cells

• Validation across methods:

  • Confirm protein expression changes with mRNA quantification

  • Consider functional assays to assess calcium ATPase activity

  • Use multiple antibodies targeting different epitopes when possible

• Statistical analysis:

  • Apply appropriate statistical tests based on data distribution

  • Use multiple comparison corrections for complex experimental designs

  • Report effect sizes alongside p-values

  • Consider biological significance beyond statistical significance

These methodological considerations ensure robust comparative analysis of ATP2A2 expression across experimental conditions.

How can ATP2A2 antibodies be utilized in studying disease mechanisms?

ATP2A2 antibodies provide valuable tools for investigating disease mechanisms:

• Darier-White disease research:

  • ATP2A2 mutations cause this autosomal dominant skin disorder

  • Antibodies can detect abnormal expression or localization in patient samples

  • Compare mutation-specific effects on protein expression and distribution

• Cardiac disease investigations:

  • ATP2A2/SERCA2 dysfunction is implicated in heart failure pathophysiology

  • Antibodies can quantify SERCA2 downregulation in failing myocardium

  • Monitor therapeutic interventions targeting SERCA2 expression or function

• Neurodegenerative disease studies:

  • Calcium dysregulation contributes to neurodegenerative processes

  • Antibodies can assess SERCA2 alterations in animal models and patient tissues

  • Investigate cell-type specific changes in SERCA2 expression

• Cancer research applications:

  • ATP2A2 has been studied in various cancer types

  • Antibodies can examine expression changes in tumor progression

  • Analyze subcellular redistribution in malignant transformation

These applications benefit from specialized immunostaining and biochemical approaches to reveal disease-specific alterations in ATP2A2 expression, localization, and function.

What considerations apply when using ATP2A2 antibodies in co-localization studies?

Co-localization studies with ATP2A2 antibodies require specific methodological considerations:

• Antibody compatibility:

  • Select primary antibodies raised in different host species

  • Verify minimal cross-reactivity of secondary antibodies

  • Consider antibody isotypes for sequential immunostaining approaches

• Subcellular localization expectations:

  • ATP2A2/SERCA2 primarily localizes to the endoplasmic/sarcoplasmic reticulum

  • Co-stain with established ER markers (e.g., calnexin, PDI)

  • Consider specialized approaches for detecting ER subdomains

• Imaging parameters:

  • Apply rigorous controls for spectral bleed-through

  • Use sequential scanning in confocal microscopy

  • Optimize pinhole settings for accurate co-localization assessment

• Quantitative co-localization analysis:

  • Calculate Pearson's or Mander's co-localization coefficients

  • Apply appropriate thresholding methods

  • Conduct statistical comparison across experimental conditions

• Advanced imaging approaches:

  • Consider super-resolution microscopy for detailed co-localization

  • Apply FRET analysis for protein proximity assessment

  • Use live-cell imaging with fluorescent protein fusions as complementary approach

Proper implementation of these considerations enables reliable assessment of ATP2A2 co-localization with interacting proteins or cellular structures.

What emerging research techniques incorporate ATP2A2 antibodies beyond traditional applications?

Innovative research applications are expanding the utility of ATP2A2 antibodies:

• Proximity-dependent labeling:

  • BioID or APEX2 fusions with ATP2A2 to identify novel interacting proteins

  • ATP2A2 antibodies validate expression and localization of fusion constructs

  • Complementary verification of identified interactors

• Single-cell protein analysis:

  • Mass cytometry (CyTOF) incorporating ATP2A2 antibodies

  • Imaging mass cytometry for spatial protein mapping

  • Single-cell Western blotting for heterogeneity assessment

• Tissue clearing and 3D imaging:

  • ATP2A2 antibody compatibility with CLARITY, iDISCO, or CUBIC protocols

  • Whole-organ imaging of calcium regulatory networks

  • 3D rendering of ATP2A2 distribution in complex tissues

• Extracellular vesicle analysis:

  • Examining ATP2A2 in exosomes and microvesicles

  • Correlating calcium dysregulation with vesicle content

  • Antibody-based capture of ATP2A2-containing vesicles

• Therapeutic monitoring:

  • Assessing treatment effects on ATP2A2 expression and function

  • Companion diagnostics for calcium modulating therapies

  • Patient stratification based on ATP2A2 status

These emerging applications extend beyond traditional Western blotting and immunostaining, offering new insights into ATP2A2 biology and pathophysiology.